The research to health policy cycle: A tool for better management of chronic noncommunicable diseases

Journal of Nephrology

Volumn 21, Issue 5, 2008, Pages 621-631

  Briggs, Tom ^a   Campbell, Norm ^b   Gordon, Deb ^c   Hemmelgarn, Brenda ^b   Husereau, Don ^d   King, Kathryn ^e   Klarenbach, Scott ^f   Manns, Braden ^b   McAlister, Finlay ^f   Ostlinger, Frank ^g   Sargious, Peter ^h   Strong, David ^a   Tonelli, Marcello ^f,i   Tsuyuki, Ross ^f   Viner, Sid ^a  

^a Health Outcomes   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c Capital Health Edmonton   (Canada)

^d CANADIAN AGENCY FOR DRUGS AND TECHNOLOGIES IN HEALTH   (Canada)

^e UNIVERSITY OF CALGARY   (Canada)

^f UNIVERSITY OF ALBERTA   (Canada)

^g Alberta Health and Wellness   (Canada)

^h Chronic Disease Management   (Canada)

ⁱ NONE   (Canada)

Author keywords

Clinical research; Health policy

Indexed keywords

ARTICLE; CHRONIC DISEASE; COST EFFECTIVENESS ANALYSIS; EPIDEMIC; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH SERVICE; HEALTH STATUS; HEALTH SURVEY; INTERVENTION STUDY; MEDICAL DECISION MAKING; MEDICAL RESEARCH; POPULATION RESEARCH; HEALTH CARE PLANNING; HEALTH SERVICES RESEARCH; HUMAN; ORGANIZATION AND MANAGEMENT;

BIOMEDICAL RESEARCH; CHRONIC DISEASE; HEALTH POLICY; HEALTH PRIORITIES; HEALTH SERVICES RESEARCH; HUMANS;

EID: 63249100909     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371:1513-1518.
2. Anderson GF, Chu E. Expanding priorities - confronting chronic disease in countries with low income. N Engl J Med. 2007;356:209-211.
3. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053.
4. Hemmelgarn BR, Zhang J, Manns BJ, et al. Progression of kidney dysfunction in the community-dwelling elderly. Kidney Int. 2006;69:2155-2161.
5. Manns BJ, Mendelssohn DC, Taub KJ. The economics of end-stage renal disease care in Canada: incentives and impact on delivery of care. Int J Health Care Finance Econ. 2007;7:149-169.
6. Canadian Organ Replacement Register. Preliminary Report for Dialysis and Transplantation. Ottawa: Canadian Institutes for Health Information; 2005.
7. Hemmelgarn BR, Manns BJ, Zhang J, et al. Association between multidisciplinary care and survival for elderly patients with chronic kidney disease. J Am Soc Nephrol. 2007;18:993-999.
8. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580-591.
9. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-1305.
10. Gao S, Manns BJ, Culleton BF, et al. Prevalence of chronic kidney disease and survival among aboriginal people. J Am Soc Nephrol. 2007;18:2953-2959.
11. Culyer AJ, Wagstaff A. Equity and equality in health and health care. J Health Econ. 1993;12:431-457.
12. Tugwell P, de Savigny D, Hawker G, Robinson V. Applying clinical epidemiological methods to health equity: the equity effectiveness loop. BMJ. 2006;332:358-361.
13. Kazanjian A. Reflections on the social epidemiologic dimension of health technology assessment. Int J Technol Assess Health Care. 2004;20:167-173.
14. Straus SE, Graham ID, Mazmanian PE. Knowledge translation: resolving the confusion. J Contin Educ Health Prof. 2006;26:3-4.
15. Glasgow RE, Lichtenstein E, Marcus AC. Why don't we see more translation of health promotion research to practice? Rethinking the efficacy-to-effectiveness transition. Am J Public Health. 2003;93:1261-1267.
16. Green LW. From research to "best practices" in other settings and populations. Am J Health Behav. 2001;25:165-178.
17. Black N. Evidence based policy: proceed with care. BMJ. 2001;323:275-279.
18. Lavis J, Davies H, Oxman A, Denis JL, Golden-Biddle K, Ferlie E. Towards systematic reviews that inform health care management and policy-making. J Health Serv Res Policy. 2005;10(Suppl 1):35-48.
19. Ross S, Lavis J, Rodriguez C, Woodside J, Denis JL. Partnership experiences: involving decision-makers in the research process. J Health Serv Res Policy. 2003;8(Suppl 2):26-34.
20. Gaziano TA, Galea G, Reddy KS. Scaling up interventions for chronic disease prevention: the evidence. Lancet. 2007;370:1939-1946.
21. Ioannidis JP. Evolution and translation of research findings: from bench to where? PLoS Clin Trials. 2006;1:e36.
22. Rothwell PM. Funding for practice-oriented clinical research. Lancet. 2006;368:262-266.
23. Johnston SC, Rootenberg JD, Katrak S, Smith WS, Elkins JS. Effect of a US National Institutes of Health programme of clinical trials on public health and costs. Lancet. 2006;367:1319-1327.
24. Contopoulos-Ioannidis DG, Ntzani E, Ioannidis JP. Translation of highly promising basic science research into clinical applications. Am J Med. 2003;114:477-484.
25. Canadian Institute for Health Information. Health indicators framework. 2008. Available at: http://secure.cihi.ca/cihiweb/products/ HealthIndicators2008_hif_en.pdf. Accessed September 4, 2008.
26. Culleton BF, Hemmelgarn B. Inadequate treatment of cardiovascular disease and cardiovascular disease risk factors in dialysis patients: a commentary. Semin Dial. 2004;17:342-345.
27. Canadian Institute for Health Information. Drug expenditure in Canada: 1985-2005. Ottawa: Canadian Institutes for Health Information; 2006.
28. Brand C, Scott I, Greenberg P, Sargious P. Chronic disease management: time for consultant physicians to take more leadership in system redesign. Intern Med J. 2007;37:653-659.
29. Clark WF, Churchill DN, Forwell L, Macdonald G, Foster S. To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy. CMAJ. 2000;162:195-198.
30. Idanpaan-Heikkila UM, Lambie L, Mattke S, McLaughlin V, Palmer H, Tu JV. Selecting indicators for the quality of cardiac care at the health system level in Organization for Economic Co-operation and Development countries. Int J Qual Health Care. 2006;18(Suppl 1):39-44.
31. McGlynn EA, Cassel CK, Leatherman ST, DeCristofaro A, Smits HL. Establishing national goals for quality improvement. Med Care. 2003;41(Suppl):I16-I29.
32. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999;282:1458-1465.
33. Kanouse DE, Kallich JD, Kahan JP. Dissemination of effectiveness and outcomes research. Health Policy. 1995;34:167-192.
34. Shepherd J, Briggs J, Payne L, Packer C, Kerridge L, Ashton-Key M. Setting the future policy agenda for health technology assessment: a specialty mapping approach. Int J Technol Assess Health Care. 2007;23:405-413.
35. Aday LA, Andersen R. A framework for the study of access to medical care. Health Serv Res. 1974;9:208-220.
36. Innvaer S, Vist G, Trommald M, Oxman A. Health policymakers' perceptions of their use of evidence: a systematic review. J Health Serv Res Policy. 2002;7:239-244.
37. Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute for Clinical Excellence (NICE). Lancet. 2002;360:711-715.
38. Diercks GF, Janssen WM, van Boven AJ, et al. Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]). Am J Cardiol. 2000;86:635-638.
39. Bryant H, Robson PJ, Ullman R, Friedenreich C, Dawe U. Population-based cohort development in Alberta, Canada: a feasibility study. Chronic Dis Can. 2006;27:51-59.
40. Glasgow RE, Wagner EH, Schaefer J, Mahoney LD, Reid RJ, Greene SM. Development and validation of the Patient Assessment of Chronic Illness Care (PACIC). Med Care. 2005;43:436-444.
41. Hofer TP, Asch SM, Hayward RA, et al. Profiling quality of care: is there a role for peer review? BMC Health Serv Res. 2004;4:9.
42. Davies MJ, Heller S, Khunti K, Skinner TC. The DESMOND educational intervention. Chronic Illn. 2008;4:38-40.
43. Davies MJ, Heller S, Skinner TC, et al. Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. BMJ. 2008;336:491-495.
44. Raftery JP, Yao GL, Murchie P, Campbell NC, Ritchie LD. Cost effectiveness of nurse led secondary prevention clinics for coronary heart disease in primary care: follow up of a randomised controlled trial. BMJ. 2005;330:707.
45. Campbell S, Reeves D, Kontopantelis E, Middleton E, Sibbald B, Roland M. Quality of primary care in England with the introduction of pay for performance. N Engl J Med. 2007;357:181-190.
46. Doran T, Fullwood C, Gravelle H, et al. Pay-for-performance programs in family practices in the United Kingdom. N Engl J Med. 2006;355:375-384.
47. Roland M. Pay-for-performance: too much of a good thing? A conversation with Martin Roland. Interview by Robert Galvin. Health Aff (Millwood). 2006;25:w412-w419.
48. Sturm H, Austvoll-Dahlgren A, Aaserud M, et al. Pharmaceutical policies: effects of financial incentives for prescribers. Cochrane Database Syst Rev. 2007;CD006731.
49. Aaserud M, Dahlgren AT, Kösters JP, Oxman AD, Ramsay C, Sturm H. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Cochrane Database Syst Rev. 2006;CD005979.
50. Austvoll-Dahlgren A, Aaserud M, Vist G, et al. Pharmaceutical policies: effects of cap and co-payment on rational drug use. Cochrane Database Syst Rev. 2008;CD007017.
51. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003;290:1624-1632.
52. Wright JM. Why don't we initiate more large simple randomized controlled trials? CMAJ. 2003;169:1170-1171.
53. Guidelines for the economic evaluation of health technologies: Canada. 3rd ed. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2006.
54. Fenwick E, Sculpher M, Claxton K, Briggs A. Improving the efficiency and relevance of health technology assessment: the role of iterative decision analytic modelling [abstract]. Annual meeting of the International Society of Technology Assessment in Health Care, York, England, 1999.
55. Levin L, Goeree R, Sikich N, et al. Establishing a comprehensive continuum from an evidentiary base to policy development for health technologies: the Ontario experience. Int J Technol Assess Health Care. 2007;23:299-309.